NCT01026441终止4 期
Clinical Study to Evaluate the Safety and Efficacy of the Vela100/eShape Uno Device for Cellulite and Circumference Reduction
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Adverse Events
研究概览
简要总结
This study is intended to test the safety of the Vela100 device when used for treatment for cellulite and circumference temporary reduction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Informed consent agreement signed by the subject.
- •Healthy males or females older than 21 years of age but not older than 60 years of age.
- •Fitzpatrick Skin Type I to VI
- •Having at least two areas (abdomen, buttocks and thighs) suitable for treatment.
- •BMI score is greater than 18.5 and less than 29.9 - normal to overweight, but not obese.
- •Willingness to follow the treatment and follow-up schedule and the post-treatment care.
- •Willingness to refrain from a change in diet/drinking/exercise/medication regimen for the entire course of the study.
- •For female of child bearing potential - using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide, or abstinence).
排除标准
- •Pregnant or planning to become pregnant, having given birth (vaginal birth or Caesarean surgery) less than 9 months ago, and/or breastfeeding.
- •Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
- •Having a permanent implant in the treated areas, such as metal plates and screws or an injected chemical substance.
- •Having received treatment with laser, RF or other devices in the treated areas within 6 months of treatment or during the study.
- •Having undergone a liposuction surgery or any contouring treatment in the areas intended for treatment within 9 months of treatment or during the study.
- •For post-liposuction areas, the procedure should also not have been performed more than 2 years prior to this study.
- •Having undergone any other surgery in the treated areas within 9 months of treatment or during the study.
- •Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions.
- •Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders.
- •Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion).
- •History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
- •Suffering from hormonal imbalance which may affect weight or cellulite, as per the Investigator's discretion.
- •History of significant lymphatic drainage problems. Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course.
- •History of keloid scarring or of abnormal wound healing.
- •History of being especially prone to bruising.
- •History of epidermal or dermal disorders (particularly if involving collagen or microvascularity).
- •Use of isotretinoin (Accutane®) within 6 months of treatment or during the study.
- •Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing agents) during, as well as two weeks before and after, the treatment course.
- •Use of anti-cellulite creams within a month of treatment or during the course of the study.
- •If any allergy that is related to the lotion used in this study appears, subjects may be excluded from the study.
- •Recently tanned in areas to be treated and/or unable or unlikely to refrain from tanning during the study.
- •Significant change in diet or exercise regimen within a month of enrollment or during this study and/or weight loss or gain of 10 lbs (4.5 kgs) within 2 months of enrollment or during this study.
- •Participation in a study of another device or drug within 1 month prior to enrollment or during this study.
- •As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
研究组 & 干预措施
Treatment for cellulite and circumference reduction
Other
All subjects will be treated with the device
干预措施: Vela100 (Aesthetic) (Device)
结局指标
主要结局
Adverse Events
时间窗: End of treatment, at 1 month FU
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Profound Dermal and SubQ Cartridges for the Treatment of CelluliteCelluliteNCT03078647Syneron Medical31
已完成
不适用
A Confirmatory Study for Evaluation of the Treatment by the Celluma3 of Periorbital WrinklesWrinkled StructureNCT02543970BioPhotas42
已完成
不适用
Safety and Effectiveness of an Auricular SprayExcessive Ear WaxNCT06085443YSLab99
已完成
不适用
Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal AtrophyVulvovaginal AtrophyNCT02085980El. En. SpA30
已完成
1 期
Evaluation of Safety and Activity of Celaderm in Healing Venous Leg UlcersVaricose UlcerLeg UlcerNCT00399308Shire40